LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC

Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as the first choice of treatment for advanced non-small-cell lung cancer. However, during the course of treatment, cancer cells often develop resistance to gefitinib without fully understood mechanisms. In this...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Ther Nucleic Acids
Main Authors: Liu, Xinyin, Lu, Xiyi, Zhen, Fuxi, Jin, Shidai, Yu, Tongfu, Zhu, Quan, Wang, Wei, Xu, Kun, Yao, Jiaqi, Guo, Renhua
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Gene & Cell Therapy 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6424064/
https://ncbi.nlm.nih.gov/pubmed/30889481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2019.02.010
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker